2',5'-Oligoadenylate Synthetase
"2',5'-Oligoadenylate Synthetase" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An enzyme that catalyzes the conversion of ATP into a series of (2'-5') linked oligoadenylates and pyrophosphate in the presence of double-stranded RNA. These oligonucleotides activate an endoribonuclease (RNase L) which cleaves single-stranded RNA. Interferons can act as inducers of these reactions.
| Descriptor ID |
D015088
|
| MeSH Number(s) |
D08.811.913.696.445.625
|
| Concept/Terms |
2',5'-Oligoadenylate Synthetase- 2',5'-Oligoadenylate Synthetase
- 2',5' Oligoadenylate Synthetase
- Synthetase, 2',5'-Oligoadenylate
- 2,5 Oligoadenylate Polymerase
- Oligoadenylate Polymerase, 2,5
- Polymerase, 2,5 Oligoadenylate
- 2',5'-Oligoadenylate Polymerase
- 2',5' Oligoadenylate Polymerase
- Polymerase, 2',5'-Oligoadenylate
- (2'-5')An Polymerase
- ATP-(2'-5')oligo(A)adenylyltransferase
- 2',5'-Oligo(A) Synthetase
- 2',5'-Oligo(A) Polymerase
- 2,5 Oligoadenylate Synthetase
- Oligoadenylate Synthetase, 2,5
- Synthetase, 2,5 Oligoadenylate
- 2-5A Synthetase
|
Below are MeSH descriptors whose meaning is more general than "2',5'-Oligoadenylate Synthetase".
Below are MeSH descriptors whose meaning is more specific than "2',5'-Oligoadenylate Synthetase".
This graph shows the total number of publications written about "2',5'-Oligoadenylate Synthetase" by people in this website by year, and whether "2',5'-Oligoadenylate Synthetase" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1995 | 1 | 0 | 1 |
| 1999 | 0 | 1 | 1 |
| 2005 | 2 | 0 | 2 |
| 2011 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "2',5'-Oligoadenylate Synthetase" by people in Profiles.
-
RAR? activation sensitizes human myeloma cells to carfilzomib treatment through the OAS-RNase L innate immune pathway. Blood. 2022 01 06; 139(1):59-72.
-
Host genetic risk factors for West Nile virus infection and disease progression. PLoS One. 2011; 6(9):e24745.
-
Gene-based intramuscular interferon-beta therapy for experimental autoimmune encephalomyelitis. Mol Ther. 2006 Sep; 14(3):416-22.
-
Single nucleotide polymorphisms in genes for 2'-5'-oligoadenylate synthetase and RNase L inpatients hospitalized with West Nile virus infection. J Infect Dis. 2005 Nov 15; 192(10):1741-8.
-
Mice deficient in oocyte-specific oligoadenylate synthetase-like protein OAS1D display reduced fertility. Mol Cell Biol. 2005 Jun; 25(11):4615-24.
-
Effects of the estrous cycle, pregnancy, and interferon tau on 2',5'-oligoadenylate synthetase expression in the ovine uterus. Biol Reprod. 2001 May; 64(5):1392-9.
-
Association of 2',5'-oligoadenylate synthetase with the prolactin (PRL) receptor: alteration in PRL-inducible stat1 (signal transducer and activator of transcription 1) signaling to the IRF-1 (interferon-regulatory factor 1) promoter. Mol Endocrinol. 2000 Feb; 14(2):295-306.
-
A phase I study of recombinant interferon-beta in patients with advanced malignant disease. Clin Cancer Res. 1999 Dec; 5(12):3990-8.
-
Lymphocytic 2',5'-oligoadenylate synthetase activity increases prior to the appearance of neutralizing antibodies and immunoglobulin M and immunoglobulin G antibodies after primary and secondary immunization with yellow fever vaccine. Clin Diagn Lab Immunol. 1995 May; 2(3):302-6.
-
Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors. Cytokine. 1994 Jul; 6(4):443-9.